Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISER: Adjuvant Rencarex in High Risk ccRCC
NCT00087022Phase 3Completed
- Sponsor
- Heidelberg Pharma AG
- Start
- Jul 2004
- Primary completion
- Oct 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing Rencarex with Placebo (2 arms). Primary endpoints: Disease-free Survival at 4.5 years and Overall Survival at 4.5 years. Started Jul 2004; status: completed.
02
Drugs
girentuximab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT00087022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087022.